Table 2.
Sensitivity, Specificity, and Predictive Values of Early Improvement for Response and Remission at Week 8
| Placebo (n=158) | Vortioxetine 10 mg (n=162) | Vortioxetine 20 mg (n=158) | Vortioxetine 10 mg or 20 mg (n=320) | |
|---|---|---|---|---|
| MADRS response | ||||
| Sensitivity (%) | 66.1 | 65.8 | 57.3 | 61.5 |
| Specificity (%) | 76.8 | 77.1 | 75.0 | 76.1 |
| Positive predictive value (%) | 62.9 | 73.2 | 71.2 | 72.3 |
| Negative predictive value (%) | 79.2 | 70.3 | 62.0 | 66.1 |
| MADRS remission | ||||
| Sensitivity (%) | 79.4 | 67.9 | 68.0 | 68.0 |
| Specificity (%) | 71.8 | 67.9 | 70.4 | 69.1 |
| Positive predictive value (%) | 43.5 | 50.7 | 51.5 | 51.1 |
| Negative predictive value (%) | 92.7 | 81.3 | 82.6 | 82.0 |
Note: MADRS response was defined as at least a 50% decrease in MADRS total score from baseline, and remission was defined as a decrease in MADRS total score to 10 or lower.
Abbreviation: MADRS, Montgomery–Åsberg Depression Rating Scale.